FindTrial
Sign In

Comparing antiemetic regimens as maintenance therapy in highly emetogenic chemotherapy.

A randomized open label trial comparing three antiemetic regimens (dexamethasone 8 mg/olanzapine 5 mg /olanzapine 10 mg) as maintenance therapy in patients who are on highly emetogenic chemotherapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/09/015742
Enrollment
240
Registered
2018-09-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Olanzapine: 10 mg per oral once a day for 4 days Control Intervention1: Dexamthasone: 8mg per oral once a day for 4 days Control Intervention2: olanzapine: 5 mg per oral once a day f

Sponsors

Dr B L Kapur hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult >18 year of age. Absence of nausea and vomiting 24 hours before. Patients up to PS-2. Adequate organ function creatinine 8. Histologically or cytologically confirmed malignant disease. Patients who will receive high emetogenic cancer chemotherapy (HEC).

Exclusion criteria

Exclusion criteria: Age > 80 years. Contraindication to steroid use. Uncontrolled diabetes. Pregnant or breast-feeding. History of psychosis. Sensitivity to olanzapine.

Design outcomes

Primary

MeasureTime frame
Yet to be decidedTimepoint: year 2021—

Secondary

MeasureTime frame
to be decidedTimepoint: year 2021—

Countries

India

Contacts

Public ContactDr Navdeep Singh

Dr B L Kapur Memorial hospital

amit.agarwal@blkhospital.com9971611311

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026